Beijing SL Pharmaceutical Co., Ltd. (002038.SZ)
- Previous Close
8.38 - Open
8.25 - Bid 8.00 x --
- Ask 8.01 x --
- Day's Range
7.81 - 8.25 - 52 Week Range
7.05 - 16.09 - Volume
29,305,414 - Avg. Volume
21,752,787 - Market Cap (intraday)
8.209B - Beta (5Y Monthly) --
- PE Ratio (TTM)
25.77 - EPS (TTM)
0.31 - Earnings Date --
- Forward Dividend & Yield 0.10 (1.19%)
- Ex-Dividend Date Jun 28, 2023
- 1y Target Est
--
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, develops, produces, and markets genetic engineering and related drugs in the People's Republic of China and internationally. The company's finished formulations includes temozolomide; arsenic trioxide; lenalidomide capsules; docetaxel; paclitaxel; recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; liraglutide; insulin aspart 30; insulin aspart 50; insulin aspart; recombinant human follitropin(rh-fsh); ciclosporin; mycophenolate mofetil dispersible; voriconazole; ornidazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; ademetionine 1,4-butanedisulfonate; glutathione; rivaroxaban; enoxaparin sodium; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; risedronate sodium; loratadine dispersible; somatostatin; octreotide acetate; calcitonin; paracetamol and tramadol hydrochloride; and etodolac. It also offers active pharmaceutical ingredients. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is headquartered in Beijing, the People's Republic of China.
www.slpharm.com.cn--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 002038.SZ
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002038.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002038.SZ
Valuation Measures
Market Cap
8.61B
Enterprise Value
7.56B
Trailing P/E
27.25
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.54
Price/Book (mrq)
1.51
Enterprise Value/Revenue
7.56
Enterprise Value/EBITDA
32.95
Financial Highlights
Profitability and Income Statement
Profit Margin
29.46%
Return on Assets (ttm)
2.41%
Return on Equity (ttm)
4.89%
Revenue (ttm)
966.9M
Net Income Avi to Common (ttm)
284.9M
Diluted EPS (ttm)
0.31
Balance Sheet and Cash Flow
Total Cash (mrq)
1.21B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-57.24M
Research Analysis: 002038.SZ
Company Insights: 002038.SZ
002038.SZ does not have Company Insights